Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
abrdn Life Sciences Investors's quarterly market cap
increased
from Mar. 2025 ($366.4 Mil) to Sep. 2025 ($459.1 Mil) and
increased
from Sep. 2025 ($459.1 Mil) to Mar. 2026 ($494.7 Mil).
abrdn Life Sciences Investors's annual market cap
increased
from Sep. 2023 ($334.1 Mil) to Sep. 2024 ($423.2 Mil) and
increased
from Sep. 2024 ($423.2 Mil) to Sep. 2025 ($459.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. abrdn Life Sciences Investors's Enterprise Value for Today is $672.3 Mil.
abrdn Life Sciences Investors (NYSE:HQL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
abrdn Life Sciences Investors Market Cap Related Terms
abrdn Life Sciences Investors Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, abrdn Life Sciences Investors's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors Market Cap vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Market Cap distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's Market Cap falls into.
abrdn Life Sciences Investors Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a Market Cap of $672.3 Mil as of Aug. 20, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on abrdn Life Sciences Investors and its competitors. According to the industry distribution chart, abrdn Life Sciences Investors ranks #422 out of 1659 companies in the Asset Management industry, placing it in the top 25.4%.
Is abrdn Life Sciences Investors' Market Cap too high?
abrdn Life Sciences Investors' current Market Cap is $672.3 Mil. The Asset Management industry median Market Cap is 199.18. abrdn Life Sciences Investors' value of $672.3 Mil is 237.5% above this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #422 out of 1659 companies in the Asset Management industry, which is above the industry midpoint. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Market Cap compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #422 out of 1659 companies for Market Cap. This puts abrdn Life Sciences Investors in the upper half of its industry. The industry median Market Cap is 199.18. abrdn Life Sciences Investors' value of $672.3 Mil is 237.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for an Asset Management company?
The median Market Cap among Asset Management companies is 199.18, based on 1,659 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current Market Cap of $672.3 Mil is 237.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median Market Cap is 199.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current Market Cap is $672.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.11 — trading 64.3% below its estimated fair value. The current Market Cap is $672.3 Mil and 237.5% above the Asset Management industry median of 199.18. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Market Cap is $672.3 Mil as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.11 is trading 64.3% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
Market Cap: $672.3 Mil
GF Value™: $62.01 vs. price of $22.11 (64.3% below fair value)
Industry Position: 237.5% above the Asset Management median (#422 of 1659)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
